Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

J Clin Oncol 2006 Jun;24(18):2707-14

University of Calgary, Calgary, Alberta, Canada; e-mail:

Purpose: Anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) are treated with surgery and radiotherapy (RT) at diagnosis, but they also respond to procarbazine, lomustine, and vincristine (PCV), raising the possibility that early chemotherapy will improve survival. Furthermore, better outcomes in AO have been associated with 1p and 19q allelic loss.

Patients And Methods: Patients with AO and AOA were randomly assigned to PCV chemotherapy followed by RT versus postoperative RT alone. The primary end point was overall survival. The status of 1p and 19q alleles was assessed by fluorescence in situ hybridization.

Results: Two hundred eighty-nine eligible patients were randomly assigned to either PCV plus RT (n = 147) or RT alone (n = 142). At progression, 80% of patients randomly assigned to RT had chemotherapy. With 3-year follow-up on most patients, the median survival times were similar (4.9 years after PCV plus RT v 4.7 years after RT alone; hazard ratio [HR] = 0.90; 95% CI, 0.66 to 1.24; P = .26). Progression-free survival time favored PCV plus RT (2.6 years v 1.7 years for RT alone; HR = 0.69; 95% CI, 0.52 to 0.91; P = .004), but 65% of patients experienced grade 3 or 4 toxicity, and one patient died. Patients with tumors lacking 1p and 19q (46%) compared with tumors not lacking 1p and 19q had longer median survival times (> 7 v 2.8 years, respectively; P < or = .001); longer progression-free survival was most apparent in this subset.

Conclusion: For patients with AO and AOA, PCV plus RT does not prolong survival. Longer progression-free survival after PCV plus RT is associated with significant toxicity. Tumors lacking 1p and 19q alleles are less aggressive or more responsive or both.

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2005.04.3414
Publisher Site
http://dx.doi.org/10.1200/JCO.2005.04.3414DOI Listing
June 2006
12 Reads

Publication Analysis

Top Keywords

progression-free survival
12
randomly assigned
12
tumors lacking
12
lacking 19q
12
survival times
8
anaplastic oligodendroglioma
8
longer progression-free
8
median survival
8
patients randomly
8
survival
8
patients aoa
8
19q alleles
8
times years
8
assigned pcv
8
pcv years
8
pcv
7
patients
7
19q
5
years
5
ratio [hr]
4

Similar Publications